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Abstract 16 
Astrocytes play a crucial role in the maintenance of the normal functions of the Central 17 
Nervous System (CNS). During the pathogenesis of neurodegenerative diseases, 18 
astrocytes undergo morphological and functional remodeling, a process called reactive 19 
astrogliosis, in response to the insults to the CNS. One of the key aspects of the reactive 20 
astrocytes is the change in the expression and function of connexins. Connexins are 21 
channel proteins that highly expressed in astrocytes, forming gap junction channels and 22 
hemichannels, allowing diffusional trafficking of small molecules. Alterations of 23 




been shown to affect the disease progression by changing neuronal function and 25 
survival. In this review, we will summarize the role of astroglial connexins in 26 
neurodegenerative diseases including Alzheimer’s disease, Huntington’s disease, 27 
Parkinson’s disease, and amyotrophic lateral sclerosis. Also, we will discuss why 28 
targeting connexins can be a plausible therapeutic strategy to manage these 29 
neurodegenerative diseases. 30 
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Neurodegenerative diseases, presented as the progressive loss of structure or function 34 
of neurons, are the main threat to human health, especially for the geriatric population. 35 
The most common forms of neurodegenerative diseases include Alzheimer's disease 36 
(AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral 37 
sclerosis (ALS) (Erkkinen et al., 2018). It is believed that different pathophysiological 38 
mechanisms causing these diseases are different and thus lead to different neurological 39 
outcomes. Some can cause memory and cognitive impairment (eg. AD and PD), and 40 
others can affect people's ability to move, speak, and breathe (eg. PD, HD, and ALS) 41 
(Abeliovich and Gitler, 2016; Canter et al., 2016; Taylor et al., 2016; Wyss-Coray, 42 
2016). However, treatment strategies which have been developed against the classical 43 
mechanisms are in-effective, yet treatments are urgently needed to stop or reverse the 44 
neurodegenerative diseases. This suggests that we may have missed some vital aspects 45 
in the bigger picture of neurodegenerative diseases.  46 
For a long time, neuron-centered theories dominated the research interest of 47 
pathogenesis of neurological disorders, whereas the critical role of astrocytes in this 48 
process had been over-looked. In the last two decades, the role of astrocytes in the 49 
healthy and diseased brain started to gain some recognition. In the adult brain, 50 
astrocytes play several crucial roles in supporting neuronal functions, including 51 
forming the blood-brain barrier by interacting with endothelial cells, providing 52 
nutrients and metabolites support to neurons, and maintaining extracellular ion balance. 53 
These functions highly depend on the coordination of hundreds of astrocytes through 54 
the formation of an astrocytic network (Santello et al., 2019), which is crucial for 55 
cognition and other CNS function. The impairment of the astrocytic network has been 56 
found in neurodegenerative diseases (Cooper et al., 2020), where astrocytes undergo 57 
reactive gliosis with morphological and functional remodeling. Such changes have been 58 
suggested to contribute to the pathogenesis of neurodegenerative diseases (Pekny and 59 




The communication between astrocytes in the astrocytic network is achieved by 61 
sharing cytoplasmic content through specific membrane units called “gap junctions”. 62 
Gap junctions allow the transcellular exchange of ions and small molecules, such as 63 
Adenosine 5′-diphosphate, glucose, glutamate, glutathione, as well as secondary 64 
messengers including cAMP and inositol triphosphate. Connexin (Cx) is a protein 65 
family that forms the structural basis of gap junctions. Cx proteins are tetraspanins with 66 
two extracellular and one intracellular loop, while the NH2- and COOH-terminal tails 67 
are located in the intracellular space (Skerrett and Williams, 2017). Cx monomers are 68 
assembled into a hexamer connexon (also called “hemichannel”) on cell membranes, 69 
and two adjacently docked connexons in the neighboring cell membranes form gap 70 
junction channels (GJCs) (Figure 1). A cluster of GJCs composes the gap junction 71 
(Nielsen et al., 2012). 72 
During reactive gliosis, the expression and function of these Cx proteins changes in 73 
astrocytes (Giaume et al., 2010; Giaume et al., 2021), especially the opening of Cx 74 
hemichannel. The opening of the hemichannel could be triggered in certain conditions, 75 
including lower pH, mechanical stimulation, oxidative stress, as well as inflammation 76 
caused by ischemic stroke and other injuries (Retamal et al., 2006; Retamal et al., 2007; 77 
Sanchez et al., 2014; Turovsky et al., 2020). The opening of Cx hemichannels can 78 
release gliotransmitters including ATP, glutamate, and D-serine, to support normal 79 
neuronal function in the physiological situation (Meunier et al., 2017). However, 80 
overactivation of Cx hemichannels found in reactive astrogliosis during 81 
neurodegeneration has been shown to disrupt the microenvironment homeostasis and 82 
contribute to disease progression (J C Vis et al., 1998; Orellana et al., 2011b; Takeuchi 83 
et al., 2011; Wang et al., 2013; Almad et al., 2016; Yi et al., 2016; Maatouk et al., 2019). 84 
In addition, the pannexin (Panx) protein family could also perform Cx-85 
hemichannel-like activity (Yeung et al., 2020). Panx usually does not form GJCs 86 
(Sosinsky et al., 2011; Sahu et al., 2014) and Panx channels have similar membrane 87 




exhibit no significant sequence homology (Yeung et al., 2020). Panx1 and Panx2 89 
expression have been found in neurons, however, their expression in astrocytes is still 90 
controversial, which may depend on the pathological condition (Vogt et al., 2005; 91 
Yeung et al., 2020).  92 
   This review will focus on the current understanding of astrocytic Cx in 93 
neurodegenerative diseases, including AD, PD, HD and ALS. We will examine how 94 
astroglial Cx, together with Panx, function as hemichannels and contribute towards the 95 
development of neurodegenerative diseases. Furthermore, we propose that astroglial 96 
hemichannels are potential therapeutic targets for the neurodegenerative diseases. 97 
CONNEXIN EXPRESSION AND FUNCTION IN ASTROCYTES 98 
In astrocytes, the dominant Cx proteins are Cx43 and Cx30, while Cx26 expression is 99 
also detectable (J E Rash et al., 2001a; J E Rash et al., 2001b). Cx43 and Cx30 normally 100 
function as GJCs, as was repeatedly shown by experiments in acute brain slices from 101 
knock out mice, including the astrocytic Cx43 conditional knockout mice (hGFAP-102 
cre:Cx43fl/fl), the Cx30 knockout mice (Dere et al., 2003; Martin Theis et al., 2003), 103 
and the double KO mice (hGFAP-cre:Cx43fl/fl:Cx30 KO) (Wallraff et al., 2006; 104 
Nathalie Rouach, 2008; Pannasch et al., 2011; Roux et al., 2011). The expression levels 105 
of these two Cxs in astrocytes varies in different brain regions(36,43), and can be 106 
changed in neurodegenerative diseases, such as AD (Yi et al., 2016; Angeli et al., 2020; 107 
Mei et al., 2010) . Additionally, Cx26 has also been detected in certain astrocytes to a 108 
lesser extent (Altevogt and Paul, 2004; Lynn et al., 2011; Nagy et al., 2011). Panx1 was 109 
reported to be expressed and also contribute to hemichannel function in reactive 110 
astrocytes in disease models (William R Silverman 2009; Karpuk et al., 2011; Marcelo 111 
F Santiago, 2011; Orellana et al., 2015; Yi et al., 2016; Maturana et al., 2017). 112 
    The CX43- and CX30-formed GJCs organize astrocytic networks with certain 113 
selectivity, which is crucial for normal neuronal function (Santello et al., 2019). For 114 




networks by transporting glutamate or glutamine(Giaume et al., 2010). In addition, the 116 
Cx30 and Cx43 mediated astrocytic networks can nourish distant neurons by mediating 117 
the delivery of glucose and lactic acid (Giaume et al., 2021; Nathalie Rouach, 2008; 118 
Clasadonte et al., 2017). Cx30 and Cx43 are also present in the astrocyte endfeet which 119 
enwrap cerebral microvessels in honeycomb-like large sized puncta that helps to 120 
represent the end-feet boundaries. This structure provides a perivascular route to 121 
mediate the exchange between neighboring end-feet (Marie Simard, 2003; Nathalie 122 
Rouach, 2008; De Bock et al., 2017). Additionally, researchers found proliferative 123 
parenchymal cells in the hypothalamus in mice were decreased in conditional Cx30 and 124 
Cx43 knock out (Recabal et al., 2018), suggesting the potential of promoting 125 
neurogenesis by manipulating Cx30 and Cx43 function. 126 
Normally, the permeability of Cx43 hemichannels is low under resting conditions 127 
(Jorge E Contreras and Bennett, 2003). They still act to modulate neuron synaptic 128 
function via the release of gliotransmitter, such as D-serine (Meunier et al., 2017). 129 
However, during reactive gliosis hemichannel permeability is dysregulated in a series 130 
of stress-associated conditions, such as inflammation (Orellana et al., 2009; De Bock 131 
et al., 2017), ischemia, oxidative stress (Ramachandran et al., 2007), or increased 132 
intracellular free Ca2+ concentration ([Ca2+]i) (De Vuyst et al., 2009). A recent study 133 
further revealed that the permeability of Cx43 hemichannels in astrocytes is modulated 134 
by cytokines and relies on the permeant species characters (Sáez et al., 2020). 135 
Furthermore, the interaction between Cx43 C-terminal tail and its cytoplasmic loop is 136 
critical for the hemichannel activity, which, in turn, can affect its GJC function 137 
(Iyyathurai et al., 2013). The SH3 binding domain and the last 9 amino acids of the C-138 
terminal tail bind to the L2/GAP19 domain of the cytoplasmic loop, allowing full 139 
activation of hemichannels (Iyyathurai et al., 2018) (Figure 1). This interaction might 140 
be regulated by phosphorylation at serine-residues in the C-terminal tail by kinases 141 
including mitogen-activated protein kinase (MAPK), protein kinase C (PKC), and 142 




2018; Freitas-Andrade et al., 2019) (Figure 1). The suppression of Cx43 144 
phosphorylation by CK1 delta can promote astrocyte survival and vascular regeneration 145 
in proliferative retinopathy (Slavi et al., 2018). 146 
In addition, Panx1 expression has also been found in cultured astrocytes (Huang et 147 
al., 2007; Bianco et al., 2009; Iwabuchi and Kawahara, 2011), and the activation of the 148 
P2X7 receptor by BzATP induced ATP release through Panx1 hemichannels instead of 149 
Cx43 hemichannels (Iglesias et al., 2009). Nevertheless, the activation of Cx43 150 
hemichannels but not Panx1 channels in vitro only occurs upon exposure to hypoxia-151 
reoxygenation, pro-inflammatory cytokines, or amyloid-beta (Aβ) treatments (Froger 152 
et al., 2010; Orellana et al., 2010; Orellana et al., 2011b). Both Cx43 hemichannels and 153 
Panx1 channels were activated in fibroblast growth factor-treated astrocyte from the 154 
spinal cord (Garre et al., 2010), and in acute brain slices from a mouse abscess model  155 
(Karpuk et al., 2011). The astrocytic Panx1 channels were also found to be activated in 156 
the APP/PS1 familial AD mouse model (Yi et al., 2016).  157 
ASTROGLIAL CONNEXINS IN AD 158 
AD is defined by progressive memory loss, behavioral deficits, and significant 159 
personality changes (Soria Lopez et al., 2019). Aβ plaques, neurofibrillary tangles, 160 
neuronal death, as well as synapse loss are characteristic features in AD brains. Notably, 161 
an invariant feature associated with Aβ plaques is reactive gliosis that includes activated 162 
microglia and reactive astrocytes (Nagele et al., 2004).  163 
Twenty years ago, Nagy and colleagues have firstly demonstrated that astrocyte 164 
Cx43 protein levels  are increased in the brain tissue of AD patients, especially around 165 
the Aβ plaques (Nagy et al., 1995), which has been repeatedly confirmed (Kajiwara et 166 
al., 2018), and is also found in the APP/PS1 mouse model (Mei et al., 2010; Yi et al., 167 
2016). However, a recent study showed that the mRNA level of Cx43 is decreased in 168 
the cortex and thalamus area of another mouse model of AD, 5xFAD mice, albeit the 169 




also results in a similar negative correlation between Cx43 mRNA and protein levels 171 
(Maulik et al., 2020). These pieces of evidence imply a possible unknown mechanism 172 
of Cx43 protein expression or turnover in AD pathology. Additionally, results from 173 
primary astrocyte culture suggested that Aβ25-35 does not alter de novo synthesized 174 
Cx43 membrane forward trafficking, but increases the internalization of Cx43, which 175 
may be responsible for the decreased GJC coupling and the increased hemichannel 176 
activity (Maulik et al., 2020). 177 
The role of astrocytic Cxs functional alteration in AD has only been identified 178 
recently, revealing that the increased Cx HC opening in AD might contribute to 179 
neuronal dysfunction. Aβ aggregates and dense core Aβ plaques can induce reactive 180 
astrogliosis in AD patients and murine AD models (Nagele et al., 2004; Verkhratsky, 181 
2010). The treatment of Aβ peptide in cultured astrocytes as well as in acute 182 
hippocampal slices has been shown to induce hemichannel opening, which releases 183 
glutamate and ATP, resulting in neuronal death (Orellana et al., 2011a). Similarly, in 184 
APP/PS1 mice, there is not only increased Cx43 and Cx30 expression in reactive 185 
astrocytes surrounding Aβ plaques, but also increased Cx43 hemichannel activity as 186 
shown in acute hippocampal slices; however, the GJC function was unaltered (Yi et al., 187 
2016). Furthermore, conditional knockout of astrocytic Cx43 in APP/PS1 mice can 188 
block hemichannel activation and lead to reduced neuronal damage in the hippocampus 189 
(Yi et al., 2016). A more recent study has also shown that specific deletion of Cx43 in 190 
astrocytes ameliorates cognitive dysfunction in APP/PS1 mice (Ren et al., 2018).  191 
These studies confirmed a critical role of astrocytic Cx43 in causing neuronal damage 192 
in the AD model, suggesting that astrocytic Cx hemichannels function could be a 193 
possible therapeutic target of AD (Figure 2). 194 
 Efforts have been made to screen or design compounds targeting astrocytic Cx 195 
proteins, in particular their hemichannel function, to ameliorate AD progression. It was 196 




of hemichannels in astrocytes and microglia without affecting GJC both in cell culture 198 
and in acute hippocampal slices (Yi et al., 2017). In the AD murine model (APP/PS1), 199 
long-term oral administration of boldine could inhibit hemichannel activation in 200 
astrocytes, accompanied by reduced intracellular Ca2+ in astrocytes, decreased 201 
gliotransmitter release, and alleviated neuronal damage in the hippocampus (Yi et al., 202 
2017). It was also found that endogenous and synthetic cannabinoid administration can 203 
reduce astrocyte Cx43 hemichannels activity and thereafter alleviate the neuronal 204 
damage in hippocampal slices exposed to Aβ (Gajardo-Gomez et al., 2017). However, 205 
more studies are required to confirm if pharmacological Cx hemichannel blockers could 206 
rescue cognitive function in AD, in order to pave the way for clinical applications. 207 
ASTROGLIAL CONNEXINS IN PD 208 
PD, as the second most common neurodegenerative disease, is characterized by 209 
progressive dopaminergic neuronal loss in the striatum and substantia nigra (Beitz, 210 
2014). The most characteristic hallmark of PD is Lewy bodies, which are cytoplasmic 211 
protein-based aggregations of α-synuclein. The clinical manifestations of PD include 212 
several motor dysfunction such as postural and movement disability, and non-motor 213 
symptoms including depression, psychosis, and dementia (Fernandez, 2012). Notably, 214 
astrogliosis in the substantia nigra plays a crucial role in PD pathogenesis (Cabezas et 215 
al., 2014).  216 
The commonly used animal model of PD is 1-methyl-4-phenyl-1,2,3,6-tet- 217 
rahydropyridine (MPTP)-lesioned striatum which leads to neurodegeneration of 218 
dopaminergic neurons. In this PD model, the expression of Cx43 and Cx30 in the 219 
striatum is increased (M Rufer et al., 1996; Fujita et al., 2018). A recent study showed 220 
that astrocytic Cx43 hemichannel permeability was also increased in the MPTP model, 221 
accompanied by elevated intracellular Ca2+ levels in the astrocytes of acute midbrain 222 
slices (Maatouk et al., 2019). The administration of a hemichannel inhibitor TAT-Gap19 223 




microglial activation (Maatouk et al., 2019). These data suggest that astrocytic Cx 225 
hemichannel opening is detrimental to the neurons in the MPTP model. However, it 226 
appears that other aspects of astrocytic Cx function might be required for neuronal 227 
survival, as Cx30 KO enhanced the loss of dopaminergic neurons in MPTP treatment 228 
(Fujita et al., 2018). In Cx30 knockout mice receiving MPTP, reactive gliosis was 229 
suppressed and the expression of neuroprotective astrocytic genes was reduced, which 230 
may contribute to the exaggerated neuronal damage (Fujita et al., 2018). However, the 231 
exact function of Cx30 in the development of PD remained unknown. Rotenone, a 232 
mitochondrial complex I inhibitor, is another neurotoxic substance commonly used to 233 
generate rodent models of PD. Rotenone administration in vivo or in vitro can increase 234 
Cx43 protein level and its phosphorylation, and GJC function in astrocytes (Kawasaki 235 
et al., 2009). 236 
Researchers also examined how α-synuclein affects astrocytic hemichannel 237 
function. It has been shown that α-synuclein also enhances the opening of Cx43 and 238 
Panx1 hemichannels in mouse cortical astrocytes, which results in the alterations in the 239 
intracellular Ca2+ dynamics, nitric oxide production, gliotransmitter release, 240 
mitochondrial morphology, and astrocyte survival (Díaz et al., 2019). This suggests that 241 
Cx43 and Panx 1 hemichannels may be involved in the pathogenesis of PD. 242 
ASTROGLIAL CONNEXINS IN HD AND ALS 243 
HD is characterized as a progressively autosomal-dominant neurodegenerative disorder, 244 
The features of HD include chorea, dystonia, cognition deficits, as well as behavioral 245 
impairments (Walker, 2007). In both healthy and diseased human brains, the 246 
distribution of Cx43 in the globus pallidus is homogeneously in the neuropil. However, 247 
in the caudate nucleus, the density of Cx43 is increased which formed in patches in HD. 248 
The immunoreactivity of the staining for glial fibrillary acidic protein (GFAP) in the 249 
astrocytes is also significantly higher in the caudate nucleus in HD brains compared to 250 




expression associated with degenerating neurons (J C Vis et al., 1998). However, the 252 
contributions of Cx hemichannels in HD have been rarely reported in recent years and 253 
thus remain to be elucidated. 254 
   ALS is characterized by progressively weakened voluntary skeletal muscles, as well 255 
as those controlling swallowing, speech, and respiration (Oskarsson et al., 2018). It is 256 
a progressive and fatal neurodegenerative disease that occurs in the younger population 257 
compared with AD and PD. Cx43 expression was found to be upregulated in the motor 258 
cortex and spinal cord of patients with ALS and in a murine model of ALS (SOD1G93A) 259 
(Díaz-Amarilla et al., 2011; Almad et al., 2016). This upregulated Cx43 expression was 260 
accompanied by an increased hemichannel activity and gap junction coupling, and 261 
subsequently elevated concentration of intracellular Ca2+, which led to motor neuron 262 
damage. In addition, the administration of pan Cx43 blocker and Cx43 hemichannel 263 
inhibitors in the ALS mouse model can alleviate the neuronal toxicity (Takeuchi et al., 264 
2011; Almad et al., 2016), suggesting that targeting Cx43 hemichannel function is a 265 
potential ALS treatment strategy. The upregulation of Panx1 expression is also found 266 
in the spinal cord of SOD1G93A mice when the symptoms become apparent (Cunha et 267 
al., 2018). However, the role of Panx1 in ALS development has not been 268 
comprehensively studied, therefore its role is still unknown. 269 
PERSPECTIVES 270 
The astrocytic GJCs and hemichannels formed by Cx proteins play important roles in 271 
neuroglial interactions. GJCs maintain neuronal homeostasis via astroglial and panglial 272 
networks for the trafficking of metabolic substances and elimination of potassium and 273 
glutamate. Under pathological conditions, the maintenance of GJC function may be 274 
beneficial as it is required for astrocytes to resist oxidative stress (Le et al., 2014). In 275 
contrast, while proper astroglial hemichannels opening is required for neuronal function 276 
under physiological conditions, hemichannel overactivation plays a detrimental role in 277 




Although it has been shown that Cx proteins could directly cause neuronal damage 279 
via hemichannel function in neurodegenerative diseases, they might also implicate in 280 
the disease pathogenesis by alternative mechanisms. Cx43 and Cx30 protein expression 281 
is enriched at the astrocyte endfeet at the gliovascular interface, and the absence of 282 
these astrocytic Cx proteins weakens the blood-brain barrier function (Ezan et al., 2012; 283 
Boulay et al., 2015), indicating a critical role of Cx proteins in the maintenance of the 284 
blood-brain barrier. Blood-brain barrier disruption has been found in neurodegenerative 285 
diseases including AD, PD, HD, and ALS (Sweeney et al., 2018; Huang et al., 2020). 286 
However, whether astrocytic Cx proteins contribute to these disease processes remains 287 
to be studied. In addition, astrocytic Cx proteins might also regulate the glymphatic 288 
pathway, which is constituted by the perivascular space wrapped by astrocytic endfeet 289 
and involved in protein waste clearance from the CNS (Rasmussen et al., 2018). 290 
Disruption of the glymphatic system has been identified in AD, which might hinder the 291 
export of Aβ protein (Nedergaard and Goldman, 2020). Considering the enrichment of 292 
Cx proteins at the astrocytic endfeet, they might also regulate glymphatic system 293 
function in neurodegenerative diseases. 294 
Given their role in several neurodegenerative diseases, Cx and Panx hemichannels 295 
can be considered as promising alternative therapeutic targets. Hemichannels appear to 296 
be more associated with neurotoxicity compared to GJCs (Froger et al., 2010; Orellana 297 
et al., 2011a; Yi et al., 2016) and their cellular localizations enable pharmacological 298 
interventions. Indeed, several strategies using genetic or pharmacological tools to block 299 
hemichannel activity have been developed in recent years (Huang et al., 2012; O'Carroll 300 
et al., 2013; Bravo et al., 2014; Chen et al., 2014). Most of them inhibit the expression 301 
and/or function of Cx43, which is regarded as the major hemichannel component in 302 
astrocytes (Nagy et al., 2004). However, they also seem to impact astroglial GJC 303 
function, which results in an inaccurate interpretation of the findings. Therefore, a tool 304 
that can specifically block hemichannel function in glial cells may delineate the future 305 
direction that reduces potential off-target effects.  306 
I  r v
i
 13 
In neurodegenerative diseases, the development of a potential treatment must 307 
consider the needs of long-term treatment and also the use of molecules with the ability 308 
to cross the blood-brain-barrier. As such, boldine, an alkaloid compound as mentioned 309 
in earlier session, can block Cx43 hemichannels in astrocytes and microglia without 310 
affecting GJCs in vitro and in acute hippocampal slices from APP/PS1 mice at the age 311 
of 9 months (Yi et al., 2017). Three-month oral administration of boldine in APP/PS1 312 
mice blocked the activation of astroglial hemichannels and ameliorated hippocampal 313 
neuritic dystrophies around the Aβ plaques (Yi et al., 2017). These results suggest that 314 
boldine seems to be a promising small molecule drug, which opens the revenue to 315 
design novel protective molecules that can alleviate neuronal toxicity under 316 
neurodegenerative conditions, especially the amyloid pathology. However, it needs to 317 
be noted that boldine has other functions, such as antioxidant and anti-inflammatory 318 
effects (Schulz et al., 2015), which can also participate in the protection of 319 
neurodegeneration in AD. Furthermore, several TAT-conjugated Cx43 peptidomimetics 320 
have been shown to block Cx43 hemichannel activity (Evans et al., 2012). For example, 321 
TAT-Gap19, a nonapeptide targeting on Cx43 extracellular loop, has been reported to 322 
exclusively block astroglial Cx43 hemichannel in a dose-dependent manner, without 323 
affecting GJCs (Abudara et al., 2014). Furthermore, in a mouse model of PD, TAT-324 
Gap19 can protect against dopaminergic neuron degeneration and microglial activation 325 
(Maatouk et al., 2019). However, TAT peptides are susceptible to proteolytic cleavage 326 
in the blood (with a half-life less than 10 min, as determined by MALDI-TOF MS 327 
Analysis) (Grunwald et al., 2009), which limits its application in chronic diseases. 328 
Structural modification is needed to increase the half-life or slow down the release in 329 
the blood. More research is also needed to identify other inhibitors with high specificity 330 
to hemichannels and long half-life to enable later clinical translation. 331 
CONCLUSION  332 




Cx43, in the pathology of neurodegenerative diseases not only in AD and PD but also 334 
in HD and ALS. Targeting astroglial Cx has become a potential strategy for the 335 
intervention or treatment of neurodegenerative diseases. Recent advances in the 336 
hemichannel opening mechanism have identified several regulatory regions in Cx43, 337 
which could facilitate the drug development targeting Cx hemichannel. 338 
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FIGURE LEGENDS 749 
 750 
FIGURE 1. Connexin formation of hemichannel. A. Connexin hexamer constitutes 751 
hemichannel, while hemichannels in the adjacent cells interact to form the gap junction 752 
channel. B. Structure of Cx43 protein. Phosphorylation sites by MAPK, CK1, and PKC 753 
in the c-terminal tail are highlighted by white circles. Regions crucial for hemichannel 754 
activation regulation was also highlighted. C. Proposed conformation changes that lead 755 
to hemichannel activation. Interaction of either CT9 or SH3-binding region with 756 
GAP19 region could achieve partial hemichannel activation, while interaction of both 757 
CT9 and SH3-binding region with GAP19 lead to fully activation of hemichannel 758 
(Iyyathurai et al., 2018). MAPK phosphorylation at S255, S262, S279 and S282 sites 759 
was proposed to facilitate interaction of SH3-binding region to the GAP19 region, 760 
enabling hemichannel activation (Freitas-Andrade et al., 2019). PKC phosphorylation 761 




2007; Hawat and Baroudi, 2008), which might act to interfere with the interaction 763 
between CT9 and GAP19 region. CK1 phosphorylation at S325, S328 and S330 has 764 
been shown to modulate hemichannel activity (Ek-Vitorín et al., 2018), but the 765 
mechanism is yet to be determined. ECM, extracellular matrix; MAPK, mitogen 766 
activated protein kinase; PKC, protein kinase C; CK1, casein kinase 1; SH3, SRC 767 
Homology 3; CT9, last 9 amino acids of the Cx43 C terminus; P labels phosphorylated 768 
amino acid residue. 769 
 770 
 771 
FIGURE 2. Schematic illustration of the role of astroglial hemichannels in 772 
neurodegeneration in an AD mouse model (APP/PS1). In the hippocampus, Cx43 HCs 773 
are activated in astrocytes contacting Aβ plaques which are triggered by high [Ca2+]i 774 
①, while Panx1 hemichannels are only activated as a minor contributor triggered by 775 
proinflammatory cytokines ② (Yi et al., 2016). HC opening results in the influx of 776 
Ca2+ from extracellular to cytoplasm, allowing the high [Ca2+]i maintenance ③ (Yi et 777 
al., 2016). HCs activation in astrocytes can lead to gliotransmitter release including 778 
glutamate and ATP ④, which then stimulate the intracellular neurotoxic cascades and 779 
resulting in neurodegeneration ⑤  (Yi et al., 2016). The astroglial connexin 780 
hemichannel blockers (such as Boldine (Yi et al., 2017), Gastrodin (Wang et al., 2013), 781 
and TAT-Gap19 (Abudara et al., 2014)) may become new pharmaceutical tools that can 782 
alleviate the neuronal damage in AD ⑥. AD, Alzheimer’s disease; HC, hemichannel; 783 
ECM, extracellular matrix. 784 
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